Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR/MSI⁃H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study

OBJECTIVE: To explore the efficacy and safety of single-agent programmed cell death protein-1 (PD-1) inhibitor in the neoadjuvant treatment of patients with mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer (LACRC) through single-center la...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xuan, Yang, Renfang, Wu, Tao, Cai, Xinyi, Li, Guoyu, Yu, Kun, Li, Yong, Ding, Rong, Dong, Chao, Li, Jinsha, Hu, Ruixi, Feng, Qing, Li, Yunfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359076/
https://www.ncbi.nlm.nih.gov/pubmed/35958603
http://dx.doi.org/10.3389/fimmu.2022.913483

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359076/
https://www.ncbi.nlm.nih.gov/pubmed/35958603
http://dx.doi.org/10.3389/fimmu.2022.913483

Ejemplares similares